Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 48, Issue 6, 1999, Pages 801-810

  Bellissant, Eric ^a,b   Giudicelli, Jean François ^a  

^a BICÊTRE HOSPITAL   (France)

^b Inst de Rech Contre le Cancer IRCC   (France)

Author keywords

Concentration effect relationship; Effect compartment; Fantofarone; Haemodynamics; Healthy volunteers; PK PD modelling; Sigmoid model

Indexed keywords

CALCIUM ANTAGONIST; FANTOFARONE; SR 33671; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HEART FUNCTION; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PR INTERVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; BRACHIAL ARTERY; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; INDOLIZINES; MALE; MODELS, BIOLOGICAL; PHENETHYLAMINES; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 0032762974     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00091.x     Document Type: Article

References (22)

1. 1 Kleinbloesem CH, Van Brummelen P, Van de Linde JA, Voogd PJ, Breimer DD. Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984; 35: 742-749.
2. 2 Graefe KH, Ziegler R, Wingender W, Rämsch KD, Schmitz H. Plasma concentration-response relationships for some cardiovascular effects of dihydropyridines in healthy subjects. Clin Pharmacol Ther 1988; 43: 16-22.
3. 3 Boyd RA, Chin SK, Don-Pedro O, et al. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther 1989; 46: 408-419.
4. 4 Colburn WA, Brazzel RK, Holazo AA. Verapamil pharmacodynamics after intravenous and oral dosing: theoretic consideration. J Clin Pharmacol 1986; 26: 71-73.
5. 5 Meredith PA, Elliott HL, Ahmed JH, Reid JL. Age and the antihypertensive efficacy of verapamil: an integrated pharmacodynamic-pharmacokinetic approach. J Hypertens 1987; 5(Suppl 5): S219-S221.
6. 6 Donnelly R, Elliott HL, Meredith PA, Kelman AW, Reid JL. Nifedipine: individual responses and concentration-effect relationships. Hypertension 1988; 12: 443-449.
7. 7 Meredith PA, Elliott HL, Donnelly R, Reid JL. Prediction of response to antihypertensive therapy with enalapril and nifedipine. J Hypertens 1989; 7(Suppl 6): S252-S253.
8. 8 Dunselman PHJM, Edgar B, Scaf AHJ, et al. Plasma concentration-effect relationship of felodipine intravenously in patients with congestive heart failure. J Cardiovasc Pharmacol 1989; 14: 438-443.
9. 9 Thuillez C, Leroy JP, Loueslati H, Bellissant E, Giudicelli JF. Débits cardiaque et régionaux non invasifs chez le volontaire sain. Intérêt prédictif. Arch Mal Coeur 1989; 82: 1275-1279.
10. 10 Meredith PA, Elliott HL, Donnelly R, Reid JL. Dose-response clarification in early drug development. J Hypertens 1991; 9(Suppl6): S356-S357.
11. 11 Chatelain P, Gubin J, Manning AS, Sissman J. SR 33557: a slow calcium channel antagonist with a novel site of action. Cardiovasc Drug Rev 1991; 9: 123-146.
12. 12 Bellissant E, Thuillez C, Kechrid R, Duhaze P, Giudicelli JF. Non invasive study of systemic and regional haemodynamic and cardiac effects of a new calcium antagonist, SR 33557, in healthy volunteers. Eur J Clin Pharmacol 1991; 41: 329-334.
13. 13 Safar ME, Peronneau PA, Levenson JA, Toto-Moukouo JA, Simon AC. Pulsed Doppler: diameter, blood flow velocity and volumic flow of the brachial artery in sustained essential hypertension. Circulation 1981; 63: 393-400.
14. 14 Bellissant E, Chau NP, Giudicelli JF. A computer program for kinetic-dynamic modeling in non steady-state experiments (Abstract). Clin Pharmacol Ther 1996; 59: 147.
15. 15 Bellissant E, Sébille V, Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 1998; 35: 151-166.
16. 16 Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-371.
17. 17 Unadkat JD, Bartha F, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 1986; 40: 86-93.
18. 18 Fuseau E, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 1984; 35: 733-741.
19. 19 Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical recipes. The Art of Scientific Computing. Cambridge. Cambridge University Press, 1986.
20. 20 Rowland M, Tozer TN. Clinical pharmacokinetics. Concepts and Applications. Philadelphia. Lea & Febiger, 1980.
21. 21 Bellissant E, Chau NP, Giudicelli JF. Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. J Cardiovasc Pharmacol 1996; 28: 470-478.
22. 22 Bellissant E, Giudicelli JF. Pharmacokinetic-pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers. Br J Clin Pharmacol 1998; 46: 383-393.